In 2017, through a multi‐omics analysis of 29 PDAC xenografts, the authors found that NPC1L1 inhibitors, such as Ezetimibe, are effective therapies for pancreatic cancer [181]. This evidence concerns the gene NPC1L1 and familial pancreatic carcinoma.